CN100513404C - 新化合物、含该化合物的药物组合物以及该化合物的应用方法 - Google Patents

新化合物、含该化合物的药物组合物以及该化合物的应用方法 Download PDF

Info

Publication number
CN100513404C
CN100513404C CNB038185563A CN03818556A CN100513404C CN 100513404 C CN100513404 C CN 100513404C CN B038185563 A CNB038185563 A CN B038185563A CN 03818556 A CN03818556 A CN 03818556A CN 100513404 C CN100513404 C CN 100513404C
Authority
CN
China
Prior art keywords
compound
alkyl
medicament
aryl
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB038185563A
Other languages
English (en)
Chinese (zh)
Other versions
CN1675192A (zh
Inventor
F·P·库哈杰达
S·M·麦德格哈尔奇
J·M·麦科法登
J·图帕里
C·A·唐森德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
FASgen Inc
Fasgen LLC
Original Assignee
Johns Hopkins University
FASgen Inc
Fasgen LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University, FASgen Inc, Fasgen LLC filed Critical Johns Hopkins University
Publication of CN1675192A publication Critical patent/CN1675192A/zh
Application granted granted Critical
Publication of CN100513404C publication Critical patent/CN100513404C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/32—Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNB038185563A 2002-07-09 2003-07-09 新化合物、含该化合物的药物组合物以及该化合物的应用方法 Expired - Fee Related CN100513404C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39458502P 2002-07-09 2002-07-09
US60/394,585 2002-07-09

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN200910203849.8A Division CN101602756B (zh) 2002-07-09 2003-07-09 化合物、含该化合物的药物组合物以及该化合物的应用方法

Publications (2)

Publication Number Publication Date
CN1675192A CN1675192A (zh) 2005-09-28
CN100513404C true CN100513404C (zh) 2009-07-15

Family

ID=30115739

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB038185563A Expired - Fee Related CN100513404C (zh) 2002-07-09 2003-07-09 新化合物、含该化合物的药物组合物以及该化合物的应用方法
CN200910203849.8A Expired - Fee Related CN101602756B (zh) 2002-07-09 2003-07-09 化合物、含该化合物的药物组合物以及该化合物的应用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN200910203849.8A Expired - Fee Related CN101602756B (zh) 2002-07-09 2003-07-09 化合物、含该化合物的药物组合物以及该化合物的应用方法

Country Status (13)

Country Link
US (2) US7649012B2 (https=)
EP (3) EP2386550A1 (https=)
JP (3) JP2005533835A (https=)
KR (1) KR101087559B1 (https=)
CN (2) CN100513404C (https=)
AU (1) AU2003265267B2 (https=)
BR (1) BRPI0312649A2 (https=)
CA (2) CA2491802C (https=)
EA (1) EA013371B1 (https=)
IL (2) IL166108A0 (https=)
MX (1) MXPA05000365A (https=)
SG (1) SG169236A1 (https=)
WO (1) WO2004005277A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101602756A (zh) * 2002-07-09 2009-12-16 法斯根公司 新化合物、含该化合物的药物组合物以及该化合物的应用方法

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2474884A1 (en) 2002-02-08 2003-08-14 John Hopkins University School Of Medicine Stimulation of cpt-1 as a means to reduce weight
BRPI0312654A2 (pt) * 2002-07-09 2017-05-02 Fasgen Llc métodos de tratar infecções microbianas em seres humanos e animais
MXPA06013687A (es) * 2004-05-26 2007-10-18 Fasgen Llc Compuestos novedosos, composiciones farmaceuticas que los contienen y metodos para utilizar los mismos.
EP2061767B1 (de) 2006-08-08 2014-12-17 Sanofi Arylaminoaryl-alkyl-substituierte Imidazolidin-2,4-dione, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Arzneimittel und ihre Verwendung
MX2009004950A (es) * 2006-11-08 2009-07-27 Fasgen Llc Nuevos compuestos, composiciones farmaceuticas que contienen los mismos, y metodos de uso de los mismos.
WO2008059214A1 (en) * 2006-11-13 2008-05-22 Astrazeneca Ab Bisamlde derivatives and use thereof as fatty acid synthase inhibitors
EP2285215A4 (en) * 2008-06-02 2012-04-04 Fasgen Inc NOVEL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREFOR AND METHOD OF USE THEREOF
UY31968A (es) 2008-07-09 2010-01-29 Sanofi Aventis Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
US8729239B2 (en) 2009-04-09 2014-05-20 Nuclea Biotechnologies, Inc. Antibodies against fatty acid synthase
US9149445B2 (en) 2009-07-27 2015-10-06 The Trustees Of Princeton University Inhibition of glycerol-3-phosphate acyltransferase (GPAT) and associated enzymes for treatment of viral infections
KR20120060207A (ko) 2009-08-26 2012-06-11 사노피 신규한 결정성 헤테로방향족 플루오로글리코시드 수화물, 이들 화합물을 포함하는 약제 및 이들의 용도
CA2798330A1 (en) 2010-05-05 2011-11-10 Infinity Pharmaceuticals, Inc. Tetrazolones as inhibitors of fatty acid synthase
US8450350B2 (en) 2010-05-05 2013-05-28 Infinity Pharmaceuticals, Inc. Triazoles as inhibitors of fatty acid synthase
WO2012120058A1 (de) 2011-03-08 2012-09-13 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120051A1 (de) 2011-03-08 2012-09-13 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683702B1 (de) 2011-03-08 2014-12-24 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8895547B2 (en) 2011-03-08 2014-11-25 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012135027A2 (en) * 2011-03-25 2012-10-04 The Research Foundation Of State University Of New York Thiolactone antibiotics
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
AU2013280980B2 (en) 2012-06-25 2017-10-19 Thomas Jefferson University Compositions and methods for treating cancer with aberrant lipogenic signaling
JP6285442B2 (ja) * 2012-09-07 2018-02-28 ヤンセン ファーマシューティカ エヌ．ベー． がん治療用の脂肪酸合成酵素（ｆａｓｎ）阻害剤として有用なイミダゾリン−５−オン誘導体
ES2753386T3 (es) 2013-03-13 2020-04-08 Forma Therapeutics Inc Derivados de 2-hidroxi-1-{4-[(4-fenil)fenil]carbonil}piperazin-1-il}etano-1-ona y compuestos relacionados como inhibidores de sintasa de ácido graso (FASN) para el tratamiento del cáncer
WO2016079317A1 (en) 2014-11-20 2016-05-26 Vib Vzw Means and methods for treatment of early-onset parkinson's disease
US10793554B2 (en) 2018-10-29 2020-10-06 Forma Therapeutics, Inc. Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone
CN114480521B (zh) * 2020-11-13 2024-07-26 中国科学院青岛生物能源与过程研究所 一种三氮菌素c的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6376682B1 (en) * 2000-02-01 2002-04-23 Takama System, Ltd. Compound with α-glucosidase inhibiting action and method for producing the same
US6380214B1 (en) * 1999-05-19 2002-04-30 Pfizer Inc. Heterocyclic derivatives useful as anticancer agents
US6391912B1 (en) * 1996-12-12 2002-05-21 Bayer Aktiengesellschaft Substituted phenylketoenols

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3496187A (en) * 1967-03-20 1970-02-17 American Home Prod N-(heterocyclyl)aconamides
US3472878A (en) * 1969-01-27 1969-10-14 American Home Prod N-(hydroxyaryl)aconamides
JPS5859920A (ja) 1981-10-05 1983-04-09 Chugai Pharmaceut Co Ltd 生体防禦能賦活剤
US4565699A (en) * 1983-07-18 1986-01-21 The Upjohn Company Composition of matter and process
US4720503A (en) * 1985-08-02 1988-01-19 Merck & Co., Inc. N-substituted fused-heterocyclic carboxamide derivatives as dual cyclooxygenase and lipoxygenase inhibitors
CH667655A5 (de) * 1986-09-24 1988-10-31 Lonza Ag Verfahren zur herstellung von 4-alkoxy-2(5h)-thiophenonen.
US4753871A (en) * 1986-12-12 1988-06-28 Eastman Kodak Company Cyan dye-forming couplers and photographic materials containing same
AU1044088A (en) * 1986-12-17 1988-07-15 Nippon Soda Co., Ltd. Heterocyclic compounds having triketo skeleton
US5759837A (en) 1989-01-17 1998-06-02 John Hopkins University Chemotherapy for cancer by inhibiting the fatty acid biosynthetic pathway
US5665874A (en) * 1989-01-17 1997-09-09 John Hopkins University Cancer related antigen
US5759791A (en) * 1989-01-17 1998-06-02 The Johns Hopkins University Cancer related antigen
US5679801A (en) * 1991-04-12 1997-10-21 American Home Products Corporation Tetronic and thiotetronic acid derivatives as phospholipase A2 inhibitors
US5614551A (en) 1994-01-24 1997-03-25 The Johns Hopkins University Inhibitors of fatty acid synthesis as antimicrobial agents
AU5762696A (en) * 1995-05-09 1996-11-29 Bayer Aktiengesellschaft Alkyl dihalogenated phenyl-substituted ketoenols useful as p esticides and herbicides
US5981575A (en) 1996-11-15 1999-11-09 Johns Hopkins University, The Inhibition of fatty acid synthase as a means to reduce adipocyte mass
JPH10212284A (ja) * 1996-11-27 1998-08-11 Sagami Chem Res Center テトロン酸−３−カルボン酸誘導体、その製造方法、製造中間体、抗がん剤、及び蛋白脱リン酸化酵素阻害剤
CO4970714A1 (es) * 1997-09-05 2000-11-07 Boehringer Mannheim Gmbh Derivados ureido y tioureido de 4-amino-2(5h)-furanonas y 4-amino-2(5h) tiofenonas como agentes antitumorales
IT1315267B1 (it) * 1999-12-23 2003-02-03 Novuspharma Spa Derivati di 2-(1h-indol-3-il)-2-oxo-acetammidi ad attivita'antitumorale
GB0000131D0 (en) * 2000-01-06 2000-02-23 Univ Cardiff Thiolactomycin analogues,compositions containing the same and uses thereof
MY134040A (en) 2001-05-02 2007-11-30 Univ New York Inhibition of pigmentation by inhibition of fatty acid synthase
CA2474884A1 (en) * 2002-02-08 2003-08-14 John Hopkins University School Of Medicine Stimulation of cpt-1 as a means to reduce weight
BRPI0312654A2 (pt) 2002-07-09 2017-05-02 Fasgen Llc métodos de tratar infecções microbianas em seres humanos e animais
EA013371B1 (ru) * 2002-07-09 2010-04-30 Фасджен, Ллс. Новые соединения, содержащие их фармацевтические композиции и способы их применения
US9690894B1 (en) 2015-11-02 2017-06-27 Altera Corporation Safety features for high level design

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391912B1 (en) * 1996-12-12 2002-05-21 Bayer Aktiengesellschaft Substituted phenylketoenols
US6380214B1 (en) * 1999-05-19 2002-04-30 Pfizer Inc. Heterocyclic derivatives useful as anticancer agents
US6376682B1 (en) * 2000-02-01 2002-04-23 Takama System, Ltd. Compound with α-glucosidase inhibiting action and method for producing the same

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101602756A (zh) * 2002-07-09 2009-12-16 法斯根公司 新化合物、含该化合物的药物组合物以及该化合物的应用方法

Also Published As

Publication number Publication date
CA2491802C (en) 2012-04-10
SG169236A1 (en) 2011-03-30
BRPI0312649A2 (pt) 2017-05-16
HK1083835A1 (zh) 2006-07-14
CA2491802A1 (en) 2004-01-15
KR20060002007A (ko) 2006-01-06
JP2005533835A (ja) 2005-11-10
CA2767092C (en) 2013-10-15
EP2386551A1 (en) 2011-11-16
IL166108A0 (en) 2006-01-15
US20100120901A1 (en) 2010-05-13
MXPA05000365A (es) 2005-09-20
AU2003265267B2 (en) 2010-03-11
KR101087559B1 (ko) 2011-11-29
EA200500178A1 (ru) 2006-02-24
EP1539730A1 (en) 2005-06-15
CN101602756A (zh) 2009-12-16
IL190218A0 (en) 2008-11-03
EP2386550A1 (en) 2011-11-16
JP2011037881A (ja) 2011-02-24
JP2013189464A (ja) 2013-09-26
CN101602756B (zh) 2014-11-12
WO2004005277A1 (en) 2004-01-15
CN1675192A (zh) 2005-09-28
US7649012B2 (en) 2010-01-19
EA013371B1 (ru) 2010-04-30
AU2003265267A1 (en) 2004-01-23
US20060247302A1 (en) 2006-11-02
EP1539730A4 (en) 2007-03-28
CA2767092A1 (en) 2004-01-15

Similar Documents

Publication Publication Date Title
CN100513404C (zh) 新化合物、含该化合物的药物组合物以及该化合物的应用方法
CN100482219C (zh) 新化合物、包含该化合物的药物组合物及该化合物的应用方法
US20110288052A1 (en) Novel compounds, pharmaceutical compositions containing same, and methods of use for same
JP2011521978A5 (https=)
US20100168176A1 (en) Novel compounds, pharmaceutical compositions containing same, and methods of use for same
US20090005435A1 (en) Novel Compounds, Pharmaceutical Compositions Containing Same, and Methods of Use for Same
HK1139676A (en) Novel compounds, pharmaceutical compositions containing same, and methods of use for same
HK1083835B (en) Novel compounds, pharmaceutical compositions containing same, and methods of use for same
US20100029752A1 (en) Novel compounds, pharmaceutical compositions containing same, and methods of use for same
US20100029761A1 (en) Novel compounds, pharmaceutical compositions containing same, and methods of use for same
HK1112837A (en) Novel compounds, pharmaceutical compositions containing same, and methods of use for same

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1083835

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1083835

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20090715

Termination date: 20150709

EXPY Termination of patent right or utility model